[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR9812114A - Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion - Google Patents

Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion

Info

Publication number
BR9812114A
BR9812114A BR9812114-6A BR9812114A BR9812114A BR 9812114 A BR9812114 A BR 9812114A BR 9812114 A BR9812114 A BR 9812114A BR 9812114 A BR9812114 A BR 9812114A
Authority
BR
Brazil
Prior art keywords
compounds
leukocyte adhesion
vla
mediated leukocyte
inhibit
Prior art date
Application number
BR9812114-6A
Other languages
Portuguese (pt)
Inventor
Eugene D Thorsett
Christopher M Semko
Dimitrios Sarantakis
Michael A Pleiss
Louis Joh Lombardo
Andrei W Konradi
Anthony Kreft
Francine S Grant
Darren B Dressen
Michael S Dappen
Reinhardt Bernhard Baudy
Susan Ashwell
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of BR9812114A publication Critical patent/BR9812114A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: <B>"COMPOSTOS DO TIPO FENILALANINA SUBSTITUìDA QUE INIBEM A ADESãO DE LEUCóCITO MEDIADA POR VLA-4"<D>. São divulgados compostos que ligam-se ao VLA-4. Certos destes compostos também inibem a adesão de leucócito e, em particular, adesão de leucócito mediada por VLA-4. Tais compostos, são úteis no tratamento de doenças inflamatórias em um paciente mamífero, por exemplo, humano, como a asma, doença de Alzheimer, ateroesclerose, demência da AIDS, diabetes, doença inflamatória do intestino, artrite reumatóide, transplante de tecido, metástase de tumor e esquemia miocardial. Os compostos são também administrados para o tratamento de doenças inflamatórias do cérebro, tais como esclerose múltipla.Invention Patent: <B> "SUBSTITUTED PHENYLALANINE TYPE COMPOUNDS THAT INHIBIT VLA-4 MEDIATED LEUKOCYTE ADHESION" <D>. Compounds that bind to VLA-4 are disclosed. Certain of these compounds also inhibit leukocyte adhesion and, in particular, VLA-4 mediated leukocyte adhesion. Such compounds are useful in the treatment of inflammatory diseases in a mammalian, for example, human patient, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, metastasis of myocardial tumor and scemia. The compounds are also administered for the treatment of inflammatory diseases of the brain, such as multiple sclerosis.

BR9812114-6A 1997-07-31 1998-07-30 Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion BR9812114A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92039497A 1997-07-31 1997-07-31
PCT/US1998/015313 WO1999006431A1 (en) 1997-07-31 1998-07-30 Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (1)

Publication Number Publication Date
BR9812114A true BR9812114A (en) 2000-07-18

Family

ID=25443662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812114-6A BR9812114A (en) 1997-07-31 1998-07-30 Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion

Country Status (16)

Country Link
EP (1) EP1001972A1 (en)
JP (1) JP2001512134A (en)
KR (1) KR20010022411A (en)
CN (1) CN1133648C (en)
AR (1) AR013384A1 (en)
AU (1) AU756696B2 (en)
BR (1) BR9812114A (en)
CA (1) CA2290747A1 (en)
HU (1) HUP0004259A3 (en)
IL (1) IL133640A0 (en)
NO (1) NO20000450L (en)
NZ (1) NZ502582A (en)
PL (1) PL338423A1 (en)
TW (1) TW534910B (en)
WO (1) WO1999006431A1 (en)
ZA (1) ZA986827B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6093696A (en) * 1997-05-30 2000-07-25 Celltech Therapeutics, Limited Tyrosine derivatives
WO1998058902A1 (en) 1997-06-23 1998-12-30 Tanabe Seiyaku Co., Ltd. INHIBITORS OF α4β1MEDIATED CELL ADHESION
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU3260399A (en) 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
JP2002535316A (en) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Fused-ring heteroaryl and heterocyclic compounds that inhibit leukocyte adhesion mediated by VLA-4
NZ529822A (en) 1999-01-22 2005-11-25 Elan Pharm Inc Acyl derivatives which treat VLA-4 related disorders
JP2002539080A (en) * 1999-01-25 2002-11-19 エラン ファーマシューティカルズ，インコーポレイテッド Compounds that inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
NZ517011A (en) * 1999-08-13 2004-02-27 Biogen Inc Cell adhesion inhibitors
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001051487A1 (en) 1999-12-28 2001-07-19 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
JP2004502762A (en) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド Squaric acid derivatives as integrin antagonists containing bicyclic heteroaromatic rings
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
IL154350A0 (en) 2000-08-18 2003-09-17 Ajinomoto Kk New phenylalanine derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
JP2004526733A (en) * 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
DE10127126A1 (en) * 2001-06-05 2002-12-19 Forschungszentrum Juelich Gmbh New protected O-(2-substituted ethyl)-L-tyrosine derivatives, useful as intermediates for the positron emission tomography contrast agent O-(2-(18F)-fluoroethyl)-L-tyrosine
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
JP2006516624A (en) * 2003-01-24 2006-07-06 エラン ファーマシューティカルズ，インコーポレイテッド Compositions for demyelinating diseases and paralysis and their treatment by administering a remyelinating agent
NZ544367A (en) * 2003-06-25 2009-12-24 Elan Pharm Inc Combination therapy involving methotrexate for treating rheumatoid arthritis
EP2803667A1 (en) 2003-12-22 2014-11-19 Ajinomoto Co., Inc. Phenylalanine derivatives
CA2714335A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
CN102057054B (en) 2008-04-11 2015-06-10 梅里麦克制药股份有限公司 Human serum albumin linkers and conjugates thereof
JP2012503595A (en) * 2008-07-28 2012-02-09 シダンスク ユニバーシティ Compounds for the treatment of metabolic diseases
CA2938945A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
JP7192139B2 (en) 2018-10-30 2022-12-19 ギリアード サイエンシーズ， インコーポレイテッド Quinoline derivatives as α4β7 integrin inhibitors
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
CN112969700B (en) 2018-10-30 2024-08-20 吉利德科学公司 Imidazopyridine derivatives as alpha 4 beta 7 integrin inhibitors
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737898B (en) * 1972-11-24 1974-07-31 Hoffmann La Roche Peptides
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
WO1992016549A1 (en) * 1991-03-18 1992-10-01 Pentapharm Ag Parasubstituted phenylalanine derivates
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
JP2001512134A (en) 2001-08-21
IL133640A0 (en) 2001-04-30
AU756696B2 (en) 2003-01-23
TW534910B (en) 2003-06-01
KR20010022411A (en) 2001-03-15
CN1133648C (en) 2004-01-07
AU8661198A (en) 1999-02-22
PL338423A1 (en) 2000-11-06
NO20000450L (en) 2000-03-28
AR013384A1 (en) 2000-12-27
WO1999006431A1 (en) 1999-02-11
HUP0004259A3 (en) 2001-05-28
NZ502582A (en) 2002-07-26
HUP0004259A2 (en) 2001-04-28
CA2290747A1 (en) 1999-02-11
EP1001972A1 (en) 2000-05-24
ZA986827B (en) 2000-05-02
CN1265668A (en) 2000-09-06
NO20000450D0 (en) 2000-01-28

Similar Documents

Publication Publication Date Title
BR9812114A (en) Substituted phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811598A (en) &#34;carbamyloxy compounds that inhibit vla-4-mediated leukocyte adhesion&#34;.
BR9811569A (en) Compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811594A (en) Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812111A (en) Dipeptide and related compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811573A (en) Benzyl compounds that inhibit vla-4 mediated leukocyte adhesion
BR9812118A (en) 4-Amino-phenylalanine-type compounds that inhibit vla-4-mediated leukocyte adhesion
BR9811599A (en) Dipetid compounds that inhibit vla-4 mediated leukocyte adhesion
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BRPI0513143A (en) multivalent vla-4 antagonists comprising polymeric moieties
ECSP045425A (en) HETEROCYCLIC COMPOUNDS THAT INHIBIT THE ADHESION OF LEUKOCYTES THROUGH INTEGRINS a4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
IL190084A (en) Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
AR029611A1 (en) COMPOUNDS THAT INHIBIT THE ADHESION OF LEUCOCITS INTERMEDIATE BY VLA-4
AR026105A1 (en) HETEROARILO, HETEROCICLICO AND ILO COMPUTERS THAT

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]